Kymera Therapeutics, Inc. Common Stock vs. Recursion Pharmaceuticals, Inc. Class A Common Stock
KYMR
Kymera Therapeutics, Inc. Common Stock
$126.64 +4.62%
VS RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock
$3.46 +6.62%
Kymera Therapeutics, Inc. Common Stock (KYMR) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| KYMR | RXRX | |
|---|---|---|
| Market Cap | $10.07 billion | $1.74 billion |
| Revenue (TTM) | $105.00 million | — |
| Net Income (TTM) | $-299,601,000 | — |
KYMR leads on 1 of 1 size & scale factors.
Valuation
| KYMR | RXRX | |
|---|---|---|
| Price / Book | 6.67 | — |
| Price / Sales | 95.86 | — |
KYMR and RXRX split the valuation factors evenly.
Profitability
| KYMR | RXRX | |
|---|---|---|
| Net Margin | -285.34% | — |
| Return on Equity | -19.85% | — |
KYMR and RXRX split the profitability factors evenly.
Risk & Sentiment
| KYMR | RXRX | |
|---|---|---|
| Short Interest | 0.24% | 0.29% |
KYMR leads on 1 of 1 risk & sentiment factors.
Dig deeper: KYMR overview, KYMR financials, RXRX overview, RXRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.